AVROBIO Inc

NASDAQ AVRO

Download Data

AVROBIO Inc Cash Dividend Coverage Ratio 3 year CAGR for the Trailing 12 Months (TTM) ending September 20, 2024

AVROBIO Inc Cash Dividend Coverage Ratio 3 year CAGR is NA for the Trailing 12 Months (TTM) ending September 20, 2024. The cash dividend coverage ratio assesses a company's ability to cover its dividend payments with its operating cash flow. It is calculated by dividing operating cash flow by dividends paid. This ratio indicates the company's capacity to generate sufficient cash flow to support dividend distributions. A ratio greater than 1 indicates a healthy coverage of dividends, while a ratio less than 1 suggests potential challenges in meeting dividend obligations. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: AVRO

AVROBIO Inc

CEO Mr. Geoff MacKay BSc
IPO Date June 21, 2018
Location United States
Headquarters Building 300, Cambridge, MA, United States, 02139
Employees 13
Sector Healthcare
Industry Biotechnology
Description

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Similar companies

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email